A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

NCT03571568 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent B-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: BI-1206
BIOLOGICAL: Rituximab
BIOLOGICAL: Acalabrutinib

Sponsor

BioInvent International AB